摘要
尿激酶型纤溶酶原激活物(uPA)是一种丝氨酸蛋白水解酶,在生理、病理条件下与细胞分化、迁移、组织重建、细胞周围基质降解有关。过去许多学者关注到,uPA在肿瘤、子宫内膜异位症、心血管疾病和自身免疫病等多种疾病的发生发展以及中枢神经系统的发育过程中发挥作用。近年来,一些关于uPA在脑缺血损伤治疗中作用的研究认为,uPA具有脑缺血损伤后神经保护的作用。当中枢神经系统发生损伤时,uPA可以经过多条通路调节中枢神经系统突触可塑性,使突触伸长、轴突再生,促进受损神经元的修复和再生,进而改善缺血后遗症,这给予了脑缺血后遗症治疗新的希望。然而,uPA发挥神经保护作用的具体机制尚未明确,uPA及相关药物在脑缺血后神经保护领域的应用仍充满了挑战。
Urokinase-type plasminogen activator(uPA)is a serine proteolytic,which plays a role in the occurrence and development of tumors and other diseases,mainly related to cell differentiation,migration,tissue reconstruction and degradation of extracellular matrix.In the past,many scholars focus on uPA's effects in the growth of central nervous system and many diseases such as cancers.In recent years,there has been some research progress of uPA in the treatment of cerebral ischemia injury.Studies suggest that uPA has a neuroprotective effect after ischemia,modulating synaptic plasticity,extending and regenerating the damaged axons,promoting the repair and regeneration of neurons and improving ischemic sequela,which gives hope to the treatment of ischemia sequela.However,the exact mechanism by which it exerts its neuroprotective effect is unclear.These factors bring challenges to the application of uPA and related drugs in the field of neuroprotection after cerebral ischemia.
作者
徐雨雯
李梦媛
邓云
薛旻
路莉
XU Yuwen;LI Mengyuan;DENG Yun;XUE Min;LU Li(Lanzhou University Second Hospital,Gansu Province,Lanzhou730030,China;Institute of Pharmacology,School of Basic Medical Sciences,Lanzhou University,Gansu Province,Lanzhou730030,China)
出处
《中国当代医药》
CAS
2022年第31期28-31,共4页
China Modern Medicine
基金
甘肃省科技计划项目(21JR7RA453)。
关键词
尿激酶型纤溶酶原激活物
脑缺血
神经保护
神经修复
药物应用
Urokinase-type plasminogen activator
Cerebral ischemia
Nerve protection
Nerve repair
Drug application
